🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to health experts.

An International Challenge

Cases of gonorrhoea are escalating globally, with estimates suggesting in excess of 82 million new cases each year. Especially elevated rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the reality of rising global incidence, escalating drug resistance and the highly restricted available drugs at this time.”

Health officials are increasingly worried about the rise in treatment-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, also known as a brand name, was cleared by the US FDA in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts hope that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization represents a significant shift in the management of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Data and Global Access

Based on data detailed in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses a dual-drug approach. The trial enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Clinicians on the front lines have shared optimism. The availability of a easy-to-administer therapy such as this is described as a "game-changer" for gonorrhoea control. This is deemed crucial to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea globally.